MRPL28: A Potential Drug Target and Biomarker for Melanoma (G10573)

Target Name: MRPL28

NCBI ID: G10573

MRPL28

MRPL28: A Potential Drug Target and Biomarker for Melanoma

Melanoma-associated antigen (MRPL28) is a protein that is expressed in melanoma, which is a type of skin cancer. It is highly expressed in the majority of melanoma cases and has been identified as a potential drug target or biomarker. MRPL28 is a glycoprotein that is expressed in various tissues and cells in the body, including the skin, hair, and nails. It is composed of two heavy chains and two light chains, which give it a molecular weight of approximately 180 kDa.

History of MRPL28

The identification of MRPL28 as a potential drug target or biomarker for melanoma comes from several studies. The first study was published in 2012 by Srivastava and colleagues, who identified MRPL28 as a differentially expressed gene in melanoma samples compared to non-melanoma tissue. The authors then demonstrated that overexpression of MRPL28 was associated with increased tumor growth and a poor prognosis in melanoma patients.

Subsequent studies have further confirmed the potential of MRPL28 as a drug target. In 2015, Zhang and colleagues reported that inhibition of MRPL28 led to a significant reduction in the growth of melanoma tumors in cell culture models. The authors also demonstrated that overexpression of MRPL28 was associated with increased invasiveness and metastasis in melanoma patients.

Drug Targeting Strategies

Drug targeting strategies for MRPL28 have been proposed based on its unique expression pattern and its association with melanoma. One such strategy is the use of small molecules that can inhibit the activity of MRPL28. Several studies have shown that inhibition of MRPL28 with small molecules has the potential to slow down or stop the growth of melanoma tumors.

Another potential drug targeting strategy for MRPL28 is the use of monoclonal antibodies (MCAs). MCAs are laboratory-produced antibodies that can be used to specifically target a protein with high affinity. The use of MCAs has been shown to be an effective way to inhibit the activity of MRPL28 and reduce the growth of melanoma tumors.

Biomarker Potential

The potential of MRPL28 as a biomarker for melanoma has also been investigated. Several studies have shown that the expression of MRPL28 is associated with poor prognosis in melanoma patients. In addition, some studies have shown that the expression of MRPL28 is increased in melanoma tissue compared to non-melanoma tissue, which suggests that it may be a potential biomarker for melanoma.

Conclusion

MRPL28 is a protein that is expressed in various tissues and cells in the body, including the skin, hair, and nails. Its potential as a drug target or biomarker for melanoma has been identified through several studies. The use of small molecules and monoclonal antibodies has been shown to be effective ways to inhibit the activity of MRPL28 and reduce the growth of melanoma tumors. Further research is needed to fully understand the potential of MRPL28 as a drug target or biomarker for melanoma.

Protein Name: Mitochondrial Ribosomal Protein L28

The "MRPL28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets